Novo Nordisk Initiates U.S. Layoffs Amid Global Restructuring, Sources Confirm
Pharmaceutical giant Novo Nordisk has commenced a significant round of layoffs in the United States, its most crucial market, according to internal communications and sources familiar with the matter. The job reductions span numerous departments including regulatory affairs, sales, and clinical development as part of a broader global restructuring initiative. The layoffs come as new CEO Mike Doustdar aims to restore investor confidence amid competitive pressures.
U.S. Workforce Reductions Underway
Novo Nordisk has initiated a substantial round of layoffs in the United States, according to reports from internal company communications and sources familiar with the situation. The Danish pharmaceutical company, known for its popular weight-loss medication Wegovy, reportedly began notifying affected U.S. employees this week, with the process expected to continue through late next week.